<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6599">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03021018</url>
  </required_header>
  <id_info>
    <org_study_id>EP0087</org_study_id>
    <nct_id>NCT03021018</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting</brief_title>
  <official_title>A Multicenter, Open-Label, Randomized, Parallel-Group, Active-Controlled Study to Assess the Efficacy and Safety of Brivaracetam Administered Intravenously as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of intravenous brivaracetam (BRV)
      compared to intravenous lorazepam (LZP) in subjects with epilepsy undergoing Epilepsy
      Monitoring Unit (EMU) evaluation who experience seizures that require prompt treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to next seizure (per clinical observation with electroencephalogram [EEG] confirmation) or rescue medication</measure>
    <time_frame>During the Treatment Period (Day 1) until Safety Follow-Up Visit (Day 2)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to next seizure (per clinical observation) or rescue medication</measure>
    <time_frame>During the Treatment Period (Day 1) until Safety Follow-Up Visit (Day 2)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who are seizure-free per clinical observation at 6 hours after the end of study drug administration</measure>
    <time_frame>At 6 hours after the end of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who are seizure-free per clinical observation at 8 hours after the end of study drug administration</measure>
    <time_frame>At 8 hours after the end of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who are seizure-free per clinical observation at 12 hours after the end of study drug administration</measure>
    <time_frame>At 12 hours after the end of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who receive rescue medication during the 6 hours after the end of study drug administration</measure>
    <time_frame>During the 6 hours after the end of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who receive rescue medication during the 8 hours after the end of study drug administration</measure>
    <time_frame>During the 8 hours after the end of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who receive rescue medication during the 12 hours after the end of study drug administration</measure>
    <time_frame>During the 12 hours after the end of study drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Brivaracetam (BRV) 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 5 ml vials of brivaracetam administered intravenously over a 2-minute period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brivaracetam (BRV) 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four 5 ml vials of brivaracetam administered intravenously over a 4-minute period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lorazepam (LZP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lorazepam bolus is to be injected based on information from the patient leaflet/package insert. The rate of injection should not exceed 2.0 mg/min. The LZP dose will be determined according to the Investigator's clinical judgment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brivaracetam</intervention_name>
    <description>Pharmaceutical Form: Solution for infusion
Concentration: 10 mg/ml
Route of Administration: intravenous</description>
    <arm_group_label>Brivaracetam (BRV) 100 mg</arm_group_label>
    <arm_group_label>Brivaracetam (BRV) 200 mg</arm_group_label>
    <other_name>Briviact</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorazepam</intervention_name>
    <description>Pharmaceutical Form: Solution for injection
Route of Administration: intravenous</description>
    <arm_group_label>Lorazepam (LZP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is male or female, 18 to 70 years of age, inclusive

          -  Subject has an established diagnosis of epilepsy

          -  Subject has been admitted to the institution's Epilepsy Monitoring Unit (EMU) for
             seizure characterization or noninvasive presurgical evaluation or such admission is
             planned within 21 days of Screening

        Exclusion Criteria:

          -  Subject has previously participated in this study and was treated with study drug.
             Re-screen is permitted

          -  Subject has participated in another study of an investigational medicinal product
             (IMP) or a medical device within the previous 30 days of Epilepsy Monitoring Unit
             (EMU) admission or is currently participating in another study of an IMP or a medical
             device

          -  Subject has taken brivaracetam (BRV) or Levetiracetam (LEV) in the 21 days prior to
             EMU admission

          -  History or presence of status epilepticus during the 6 months prior to EMU admission

          -  Subject has a medical or psychiatric condition that in the opinion of the
             Investigator could jeopardize or would compromise the subject's ability to
             participate in this study

          -  Subject has &gt; 2x upper limit of normal (ULN) of any of the following: alanine
             aminotransferase, aspartate aminotransferase, alkaline phosphatase, or &gt; ULN total
             bilirubin

          -  Subject has chronic liver disease

          -  Subject has hypersensitivity to BRV or any of its excipients

          -  Subject has a history of alcohol or drug abuse during the 6 months prior to EMU
             admission

          -  Subject with a history of psychogenic seizures

          -  Subject is a pregnant or lactating female

          -  Subject has a history of a significant Adverse Event (AE) due to a benzodiazepine in
             the opinion of the Investigator

          -  Subject has respiratory failure (or is at risk for respiratory failure), untreated
             sleep apnea, or other severe cardiorespiratory disease with New York Heart
             Association Class III or IV functional status, or requires supplemental oxygen

          -  Subject has acute narrow-angle glaucoma or myasthenia gravis

          -  Subject is receiving benzodiazepine treatment (defined as an average of &gt;=4
             administrations per week) that started less than 28 days prior to EMU admission

          -  Subject has a known allergic reaction or intolerance to benzodiazepines or
             benzodiazepine excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>UCB (+1 877 822 9493)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UCB Cares</last_name>
    <phone>+1877822</phone>
    <phone_ext>9493</phone_ext>
  </overall_contact>
  <location>
    <facility>
      <name>Ep0087 112</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ep0087 103</name>
      <address>
        <city>Boston</city>
        <state>Maryland</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ep0087 101</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ep0087 105</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 5, 2017</lastchanged_date>
  <firstreceived_date>January 11, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>Brivaracetam</keyword>
  <keyword>Epilepsy Monitoring Unit</keyword>
  <keyword>Increased seizure activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lorazepam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
